To effect change, we must address health care disparities beyond the individual level, says Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health and director of the Center for Health, Identity, Behavior and Prevention Studies.
Social stressors—discrimination, homophobia, racism, misogyny—create psychosocial burdens, so to create change, we can’t just address disparities on the societal level for individuals, says Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health and director of the Center for Health, Identity, Behavior and Prevention Studies; we must address them on social, structural, behavioral, and biological levels as well.
This video excerpt is the third entry in a series on individuals and international organizations working to bring local and global awareness to the ongoing HIV/AIDS epidemic, which is marking its 40th anniversary this year. For previous entries, click here.
Transcript
Can you tell us about yourself and your work?
I'm Perry Halkitis. I am the dean of the School of Public Health at Rutgers University. For over 2 decades, my work has focused on infectious diseases, specifically HIV, and the intersection of infectious diseases with social and structural and behavioral determinants. And the syndemic, or the comorbidity, that often exists with the transmission of infectious disease, like HIV, with drug abuse and mental health.
I’ve primarily looked at these connections, and I've developed interventions, in the LGBTQ+ population, but not exclusively. And so that's been the focus of my work. Really community-engaged, activist-led, high-level scholarship trying to eradicate these disparities in our society.
How can we address the inordinate rates of drug abuse and HIV that contribute to health disparities within the LGBTQ community?
There are structural inequities that drive disparities. People don't wake up one morning deciding that they should have a drug addiction or they should acquire HIV or they should get COVID or they should be obese or they should smoke cigarettes, right? These are situations and health conditions that emerge in people's lives.
We have focused too much on the individual-level intervention, like how do we get people to stop smoking? How do we get people to stop drinking? How do we prevent people from acquiring HIV? My argument is that those kind of behavioral interventions are good, but insufficient, and that what we really need to do is think about what are the conditions that fuel these behaviors in people. Why is it that we see such high levels of psychopathology in LGBTQ people? Why do we see such high levels of drug use?
My argument is that for the LGBTQ population and other populations, which are discriminated [and] marginalized, there are these social stressors—discrimination, homophobia, racism, misogyny—that create psychosocial burdens in people's lives, that create stressors which engender risk. And as a result, they place themselves at risk for potential problems.
And so I think that if you want to effect a change, you need to effect the change on the social level, the structural level, the behavioral level, and the biological level, all in combination.
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More